- Home
- FSP vs INZY Comparison
FSP vs INZY Comparison
Compare FSP & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSP
- INZY
- Stock Information
- Founded
- FSP 1981
- INZY 2015
- Country
- FSP United States
- INZY United States
- Employees
- FSP N/A
- INZY N/A
- Industry
- FSP Real Estate Investment Trusts
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- FSP Real Estate
- INZY Health Care
- Exchange
- FSP Nasdaq
- INZY Nasdaq
- Market Cap
- FSP 187.5M
- INZY 188.2M
- IPO Year
- FSP N/A
- INZY 2020
- Fundamental
- Price
- FSP $1.76
- INZY $1.36
- Analyst Decision
- FSP
- INZY Strong Buy
- Analyst Count
- FSP 0
- INZY 8
- Target Price
- FSP N/A
- INZY $17.75
- AVG Volume (30 Days)
- FSP 229.5K
- INZY 1.0M
- Earning Date
- FSP 02-24-2025
- INZY 03-11-2025
- Dividend Yield
- FSP 2.26%
- INZY N/A
- EPS Growth
- FSP N/A
- INZY N/A
- EPS
- FSP N/A
- INZY N/A
- Revenue
- FSP $126,508,000.00
- INZY N/A
- Revenue This Year
- FSP N/A
- INZY N/A
- Revenue Next Year
- FSP $0.02
- INZY N/A
- P/E Ratio
- FSP N/A
- INZY N/A
- Revenue Growth
- FSP N/A
- INZY N/A
- 52 Week Low
- FSP $1.47
- INZY $1.24
- 52 Week High
- FSP $2.47
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- FSP 46.08
- INZY 29.28
- Support Level
- FSP $1.75
- INZY $1.35
- Resistance Level
- FSP $1.88
- INZY $1.62
- Average True Range (ATR)
- FSP 0.06
- INZY 0.13
- MACD
- FSP -0.00
- INZY 0.04
- Stochastic Oscillator
- FSP 26.13
- INZY 32.89
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.